Market capitalization | $5.74m |
Enterprise Value | $8.24m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 29.43 |
P/S ratio (TTM) P/S ratio | 20.50 |
P/B ratio (TTM) P/B ratio | 4.58 |
Revenue (TTM) Revenue | $280.00k |
EBIT (operating result TTM) EBIT | $-19.09m |
Cash position | $4.58m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:
2 Analysts have issued a Evaxion Biotech A/S - ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.28 0.28 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -19 -19 |
23%
23%
|
Net Profit | -15 -15 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on 11 August, 2008 and is headquartered in Copenhagen, Denmark.
Head office | Denmark |
CEO | Christian Kanstrup |
Employees | 49 |
Founded | 2008 |
Website | www.evaxion-biotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.